90Y-FAPi-04 is the therapeutic analogue of the PET imaging agent 68Ga-FAPi-04 from the FAPi family developed at the Cancer Research Center of Heidelberg, Germany. It is a DOTA-coupled quinolone analogue radiotherapeutic based on a Fibroblast Activation Protein (FAP)-specific enzyme inhibitor (FAPi). The same molecule has already been labeled with 177Lu.
90Y-FAPi-04 is presently in Phase 0 clinical trial.
Radiotherapeutics
Y-90-FAPI-04

- Target/Mechanism
- Fibroblasts
- Carrier/Ligand
- FAPI-04
- Radiation Type
- beta (β–)